09.08.2012 • News

Eli Lilly Raises 2012 Net Profit Forecast

Eli Lilly on Thursday raised its net profit forecast for 2012 to reflect income from the early payment of financial obligations from former partner Amylin Pharmaceuticals, which has been acquired by Bristol-Myers Squibb.

It said it now expects net earnings per share to range between $3.72 and $3.82. Its forecast for earnings excluding one-time items remains unchanged.

 

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read